The report, from Gary Siuzdak and Howard Fox of the Scripps Research Institute in La Jolla, California, shows the potential of metabolomics, a comprehensive cataloguing of small molecules, to yield biomarkers for CNS conditions, possibly including Alzheimer disease and other neurodegenerative disorders.